Latest news with #Oculis
Associated Press
7 days ago
- Business
- Associated Press
Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) ('Oculis'), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs, today announced that Oculis' management will be participating in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025. Links to access the corporate update presentation and the panel discussion will be posted to Oculis' website on the Events & Presentation page under the Investors & Media section. About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs. Oculis' highly differentiated late-stage clinical pipeline includes three core product candidates: OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema; Privosegtor (OCS-05), a neuroprotective candidate in Phase 2 for acute optic neuritis, with potentially broad clinical applications in various neuro-ophthalmic and neurological diseases; and Licaminlimab (OCS-02), a novel topical anti-TNFα in Phase 2, being developed with a genotype-based approach to drive personalized medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. For more information, please visit: Oculis Contacts Ms. Sylvia Cheung, CFO [email protected] Investor Relations LifeSci Advisors Corey Davis, Ph.D. [email protected] Media Relations ICR Healthcare Amber Fennell / David Daley / Sean Leous [email protected]
Yahoo
03-06-2025
- Business
- Yahoo
Oculis to Participate in Upcoming June Investor Conferences
ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: ('Oculis'), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be participating in the following upcoming investor conferences: Goldman Sachs Annual Healthcare ConferenceJune 9-11; Miami, FL, chat with Riad Sherif, MD, Chief Executive Officer, on June 10th from 9:20 to 9:55am ET. J.P. Morgan European Healthcare Conference June 12; London, Sherif, MD, Chief Executive Officer, will be attending. The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings. Webcast links, when available, will be posted to the Oculis website on the Events & Presentation page under the Investors & Media section. -ENDS- About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. Oculis' highly differentiated pipeline of multiple innovative product candidates in development includes: OCS-01, a topical eye drop candidate for diabetic macular edema (DME); Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. For more information, please visit: Oculis ContactsMs. Sylvia Cheung, Investor Relations LifeSci AdvisorsCorey Davis, Media Relations ICR Healthcare Amber Fennell / David Daley / Sean Leous oculis@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
